TriSalus Life Sciences (NASDAQ:TLSI) Issues Quarterly Earnings Results

TriSalus Life Sciences (NASDAQ:TLSI) released its earnings results on Tuesday. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02), FiscalAI reports. The firm had revenue of $12.88 million for the quarter, compared to the consensus estimate of $14.02 million.

Here are the key takeaways from TriSalus Life Sciences’ conference call:

• Negative sentiment: Third-quarter revenue rose 11% year over year to $12.9 million, but growth was below expectations. TriSalus lowered its 2026 revenue outlook to $46 million–$48 million, or 2%–6% growth, citing slower productivity in new sales territories and a shift toward super-selective Y90 procedures.
• Positive sentiment: FDA clearance of TriNav Advance extends the company’s technology to small distal vessels, addressing procedures it previously could not fully serve. A limited release is underway; management said the product is not included in fourth-quarter revenue guidance.
• Positive sentiment: CMS finalized higher 2027 Medicare payment for Y90 mapping procedures and national pricing of about $13,788 for PEDD procedures in office-based labs. Management expects the changes to strengthen reimbursement and expand access across care settings.
• Positive sentiment: Gross margin improved to 86%, adjusted EBITDA loss narrowed to $4.7 million, and the company ended the quarter with about $41 million in cash, which management said funds its strategic growth plan.
• Neutral sentiment: TriSalus reported 11 active studies across 27 clinical sites and plans to advance comparative studies in liver cancer segments, alongside research in other indications. Upcoming evidence and publications could support adoption, though many milestones remain prospective.

TriSalus Life Sciences Stock Down 2.4%

TLSI stock traded down $0.06 during mid-day trading on Thursday, hitting $2.25. 144,349 shares of the company were exchanged, compared to its average volume of 298,010. TriSalus Life Sciences has a 1-year low of $2.20 and a 1-year high of $7.95. The company has a debt-to-equity ratio of 5.05, a quick ratio of 4.97 and a current ratio of 5.35. The firm’s 50 day simple moving average is $4.15 and its 200 day simple moving average is $4.32. The firm has a market cap of $138.24 million, a P/E ratio of -4.57 and a beta of 0.50.

Wall Street Analyst Weigh In

TLSI has been the topic of a number of recent analyst reports. Stifel Nicolaus set a $12.00 price target on TriSalus Life Sciences in a report on Wednesday, September 23rd. Guggenheim set a $12.00 target price on shares of TriSalus Life Sciences in a research report on Wednesday, September 23rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TriSalus Life Sciences in a research note on Wednesday, November 4th. Citigroup reaffirmed a “buy” rating on shares of TriSalus Life Sciences in a research report on Tuesday. Finally, Canaccord Genuity Group cut their price target on TriSalus Life Sciences from $7.00 to $4.00 and set a “buy” rating for the company in a report on Tuesday. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $9.20.

About TriSalus Life Sciences

TriSalus Life Sciences is a medical technology and oncology company developing ways to improve the delivery of treatments to solid tumors. Its Pressure-Enabled Drug Delivery (PEDD) platform is designed to increase the distribution of therapeutic agents within tumor tissue by using controlled pressure during infusion. The company’s TriNav® infusion system is designed to deliver therapies to the liver through the hepatic artery. TriSalus is also developing PEDD-based approaches for liver and pancreatic tumors, including use with its investigational immunotherapy SD-101, a toll-like receptor 9 agonist.